HOME >> BIOLOGY >> NEWS
Millennium and Bayer industrializing drug discovery process through ongoing successful research alliance

More Than 70 disease-relevant validated drug targets moving in to or beyond screening in first two years of collaboration

CAMBRIDGE, Mass. and LEVERKUSEN, Germany, October 24, 2000 --Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Bayer AG today announced that they are currently moving more than 70 disease-relevant validated drug targets into high-throughput screening or lead identification in the first two years of their five-year research alliance. The alliance achieved these exceptional advances through joint efforts. The two companies collaborated to streamline the drug discovery process with Millennium industrializing the rapid identification, characterization and validation of target proteins and Bayer conducting large-scale high-throughput screening. This innovative approach to target discovery allows for the categorization of genes with disease relevance and is a key step in the process to enhance the productivity of drug discovery.

The alliance is centered on genomics research that identifies the composition and function of thousands of genes which carry instructions to make proteins the body needs to function. By integrating large-scale genetics, genomics, automation, informatics and drug discovery technologies, Millennium can rapidly search for disease-relevant targets that are promising for drug development. This resulting drug discovery platform, which effectively meets the needs of the research alliance with Bayer, serves all of Millenniums research programs, both internal and partnered, and contributes validated targets to the Companys own drug discovery pipeline.

With the aid of Bayers high-throughput robotic screening technology, the selected targets are incorporated into test systems to search for compounds that show promise for drug development. This screening process can test more than 200,000 such compounds daily.

The progress of the Millennium and Bayer alliance in its first tw
'"/>

Contact: Maureen Suda, Millennium Pharmaceuticals Inc.
617-551-2959
Porter Novelli
23-Oct-2000


Page: 1 2 3

Related biology news :

1. Millenniums LDP(PS)-341 inhibits growth and induces death of cancer cells, appears to overcome chemotherapy resistance
2. Science and Technology at the Millennium: Retrospect or Prospect Focus of AAAS Science and Technology Colloquium, April 11-13 in Washington, DC
3. Millennium and Wyeth-Ayerst announce the discovery of key potassium ion channel modulating proteins
4. Millennium and the Whitehead Institute identify novel protein important in fat absorption
5. Millennium Clones Diet-Induced Obesity Gene
6. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
7. New OHSU lab will speed drug discovery process
8. New discovery may help transplants survive
9. Genetic discovery could dramatically reduce need for liver transplants in children
10. Plant gene discovery could enhance plant growth, reduce fertilizer needs and phosphate pollution
11. Major scientific discovery in cancer research to be honored

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... ... September 19, 2017 , ... Molecular Devices, LLC, a ... GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. This novel ... and provide visual documentation of monoclonality for use in cell line development. ...
(Date:9/18/2017)... 2017   Montrium , a growing leader in Electronic ... with a groundbreaking non-profit research organization, Multidisciplinary Association for Psychedelic ... MAPS ... PTSD ... Therapy Designation to MDMA for the treatment of Posttraumatic Stress Disorder ...
(Date:9/14/2017)... PA and London UK (PRWEB) , ... September ... ... will gather the most innovative minds in pharma and biotech at the third ... a two-day collaborative conference that brings together the world’s most progressive clinical research ...
(Date:9/14/2017)... ... 14, 2017 , ... AIM Global, the worldwide standards agency for AIDC and ... 2017 Case Study Competition for AIDC. The award is given to those in ... push the adoption of automated data collection systems further. The TRACTUS platform, by ...
Breaking Biology Technology:
Cached News: